Real-world effectiveness of the Oxford/Astrazeneca COVID-19 vaccine in England (RAVEN)
This is a retrospective cohort study to assess the real world effectiveness of the Oxford/Astrazeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death. The interim analysis will focus on effectiveness of the 1st dose. The final analysis will look at both doses.
Objectives and Hypotheses:
Primary: To assess the real world effectiveness of the Oxford/Astrazeneca COVID-19 vaccine among people who receive one dose of the vaccine, overall and by age group and time period after 1 dose
Secondary:
1. To assess the real world effectiveness of the Oxford/Astrazeneca COVID-19 vaccine in people vaccinated with two doses; and by timing after the 1st and 2nd dose, interval between the two doses, and comorbidity status
2. To assess the effectiveness of the Pfizer COVID-19 vaccine among people who received one dose and two doses, overall and by age group, time periods after each dose, and interval between the two doses
Study Team
- Principle Investigator: Prof Simon de Lusignan
- Co-investigator: Prof F D Richard Hobbs
- Co-investigator: Prof David Clifton
- Co-investigator: Prof Lisa White
- Co-investigator: Dr Mark Joy
- Co-investigator: Dr James Sheppard
